Tonix and Makana partner on xenotransplantation research
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company valued at $127.54 million, and Makana Therapeutics, Inc., specializing in xenotransplantation, have entered into a research collaboration to explore the use of Tonix’s TNX-1500 in conjunction with Makana’s genetically engineered pig organs. This partnership aims to reduce organ rejection in patients undergoing xenotransplantation. According to InvestingPro data, Tonix maintains a healthy financial position with a current ratio of 6.5, indicating strong short-term liquidity.
The preclinical studies will support the submission of an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for potential compassionate use in human recipients. TNX-1500 is an anti-CD40L monoclonal antibody candidate designed to modulate immune responses, which is crucial for preventing organ rejection. The company has demonstrated strong revenue growth of 29.94% over the last twelve months, reflecting its advancing pipeline development. InvestingPro subscribers can access 13 additional key insights about Tonix’s financial health and market position.
Makana’s genetically engineered pigs, specifically designed without certain antigens, have demonstrated improved compatibility with human immune systems. These advances could potentially lead to a more reliable supply of organs for transplantation. The partnership focuses on kidney, heart, and islet cell transplant programs.
Tonix’s CEO, Seth Lederman, expressed enthusiasm for the collaboration’s potential to bring xenotransplantation into clinical settings. Makana’s founder, Joseph Tector, highlighted the critical role of anti-CD40L in successful xenotransplantation, noting that TNX-1500 has shown promise in previous studies.
Makana’s President and CEO, Mark Platt, emphasized the significance of the collaboration for advancing clinical development, given the scarcity of organ transplants for patients with organ failure.
This research agreement is based on a press release statement and represents a strategic step towards addressing the persistent challenge of organ compatibility and rejection in transplantation. The company’s stock has shown significant momentum with a 13.97% return over the past week, and investors can track its next earnings release scheduled for May 12, 2025. For comprehensive analysis and real-time updates, visit InvestingPro.
In other recent news, Tonix Pharmaceuticals Holding Corp. has made significant strides with its investigational drug TNX-102 SL, aimed at treating fibromyalgia. The U.S. Food and Drug Administration (FDA) announced it will not require an Advisory Committee meeting for the drug’s New Drug Application, which is often a positive indicator of a smooth review process. TNX-102 SL has been granted Fast Track designation, and its Prescription Drug User Fee Act (PDUFA) goal date is set for August 15, 2025. Tonix is preparing for a potential commercial launch in the fourth quarter of 2025, should the drug receive approval.
Additionally, Tonix Pharmaceuticals launched TONIX ONE, a digital platform designed to enhance migraine management through educational resources, telehealth services, and e-prescription facilitation. This platform is part of a strategic collaboration with partners like UpScript Telemedicine and Blink Health. In another development, Noble Capital has maintained its Outperform rating on Tonix Pharma, with a $70 price target, underscoring confidence in the company’s prospects. These recent developments reflect Tonix Pharmaceuticals’ ongoing efforts to innovate and expand its treatment options in the biopharmaceutical sector.
